PR671, the first proteasome inhibitor that selectively inhibits the bortezomib/carfilzomib insensitive β2 proteasome subunits, overcomes bortezomib/carfilzomib resistance in myeloma cells in vitro

被引：0
|
作者：
Driessen, C. [1 ]
Kraus, M. [1 ]
van der Linden, W. A. [2 ]
Bader, J. [1 ]
Overkleeft, H. S. [2 ]
机构：
[1] Kantonsspital, St Gallen, Switzerland
[2] Leiden Univ, Inst Chem, Leiden, Netherlands
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：176 / 176
页数：1
相关论文
共 36 条
  • [21] The proteasome inhibitor bortezomib stimulates the osteogenic differentiation of mesenchymal cells in vitro and may increase osteoblast formation in vivo in multiple myeloma patients
    Giuliani, N.
    Morandi, F.
    Tagliaferri, S.
    Lazzaretti, M.
    Bonomini, S.
    Crugnola, M.
    Mancini, C.
    Martella, E.
    Ferrari, L.
    Tabilio, A.
    Rizzoli, V
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 32 - 32
  • [22] The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    Hideshima, T
    Richardson, P
    Chauhan, D
    Palombella, VJ
    Elliott, PJ
    Adams, J
    Anderson, KC
    [J]. CANCER RESEARCH, 2001, 61 (07) : 3071 - 3076
  • [23] The proteasome inhibitor PR-171 inhibits cell growth, induces apoptosis, and overcomes de novo and acquired drug resistance in human multiple myeloma cells.
    Ivancsits, D
    Nimmanapali, R
    Sun, M
    Shenk, K
    Demo, SD
    Bennett, MK
    Dalton, WS
    Alsina, M
    [J]. BLOOD, 2005, 106 (11) : 452A - 452A
  • [24] 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27
    Chauhan, D
    Li, G
    Auclair, D
    Hideshima, T
    Podar, K
    Mitsiades, N
    Mitsiades, C
    Chen, LB
    Munshi, N
    Saxena, S
    Anderson, KC
    [J]. APOPTOSIS, 2004, 9 (02) : 149 - 155
  • [25] 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27
    D. Chauhan
    G. Li
    D. Auclair
    T. Hideshima
    K. Podar
    N. Mitsiades
    C. Mitsiades
    L. B. Chen
    N. Munshi
    S. Saxena
    K. C. Anderson
    [J]. Apoptosis, 2004, 9 : 149 - 155
  • [26] Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy
    Schewe, Denis M.
    Aguirre-Ghiso, Julio A.
    [J]. CANCER RESEARCH, 2009, 69 (04) : 1545 - 1552
  • [27] The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib
    Driessen, Christoph
    Bader, Juergen
    Kraus, Marianne
    [J]. BLOOD, 2010, 116 (21) : 1657 - 1658
  • [28] The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma (MM) cells.
    Hideshima, T
    Richardson, PG
    Chauhan, D
    Palombella, VJ
    Elliott, PJ
    Adams, J
    Anderson, KC
    [J]. BLOOD, 2000, 96 (11) : 461A - 461A
  • [29] The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells
    Pei, XY
    Dai, Y
    Grant, S
    [J]. LEUKEMIA, 2003, 17 (10) : 2036 - 2045
  • [30] PROTEASOME INHIBITOR, BORTEZOMIB, OVERCOMES RESISTANCE TO TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) IN TREATMENT-REFRACTORY MALIGNANT HUMAN GLIOMA CELLS
    Kang, Peter
    Jane, Esther P.
    Premkumar, Daniel R.
    Pollack, Ian F.
    [J]. NEURO-ONCOLOGY, 2010, 12 : 93 - 93
1234